Myasthenia Gravis Market’s CAGR of 9.3%: Key Players
According to a newly published market research report by 24LifeSciences, global Myasthenia Gravis disease market was valued at USD 1.05 billion in 2025 and is projected to grow from USD 1.15 billion in 2026 to reach USD 1.93 billion by 2034, growing at a compound annual growth rate (CAGR) of 9.3% during the forecast period.
Myasthenia Gravis, clinically known as a chronic autoimmune neuromuscular disorder, is characterized by fluctuating weakness of voluntary muscle groups due to antibodies attacking acetylcholine receptors at neuromuscular junctions. Its established clinical presentation includes symptoms such as ptosis, diplopia, dysphagia, and generalized fatigue, requiring specialized neurological care and long-term therapeutic management.
Download a Free Sample Report (PDF): https://www.24lifesciences.com..../download-sample/954
